View in EDS HTML Full Text PDF Full Text

Weekly vs. 3-weekly paclitaxel, carboplatin, and cetuximab (PCC) in recurrent/metastatic head and neck cancer.

Saved in:
Bibliographic Details
Title: Weekly vs. 3-weekly paclitaxel, carboplatin, and cetuximab (PCC) in recurrent/metastatic head and neck cancer.
Authors: Geraghty, Leeann1 (AUTHOR), Schultz, Thomas E.2 (AUTHOR), Hoffman, Sarah E.2 (AUTHOR), Porter, Kyle3 (AUTHOR), Issa, Majd4 (AUTHOR), Karivedu, Vidhya4 (AUTHOR), Bonomi, Marcelo4 (AUTHOR) Marcelo.Bonomi@osumc.edu
Source: Molecular & Clinical Oncology. Nov2021, Vol. 15 Issue 5, pN.PAG-N.PAG. 1p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:20499450
DOI:10.3892/mco.2021.2403